Cochrane · systematic review · CD008214
Anti‐vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy
Dervenis, P, Dervenis, N, Smith, JM, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 2 · 28.6%Moderate 2 · 28.6%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings
Population: people with proliferative diabetic retinopathy undergoing vitrectomy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean BCVA (logMAR) | no estimate extracted | 13 studies · 699 participants | Low Downgraded: inconsistency |
Early POVCH Â | RR 0.44 [0.34, 0.58] | 14 studies · 1038 participants | Moderate Downgraded: risk of bias |
Late POVCH Â | RR 0.47 [0.3, 0.74] | 11 studies · 579 participants | High |
Revision surgery for POVCH | RR 0.44 [0.15, 1.28] | 4 studies · 207 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Revision surgery for recurrent traction and/or RRD | RR 0.5 [0.15, 1.66] | 4 studies · 145 participants | Low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Intraoperative retinal breaks | RR 0.37 [0.24, 0.59] | 12 studies · 915 participants | High |
Silicone oil use | RR 0.46 [0.27, 0.8] | 10 studies · 591 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |